Corvas International, Inc.

Sanford Burnham Prebys Medical Discovery Institute

Sanford-burnham Medical Research Institute

Other

E.i. Dupont De Nemours and Company

Eli Lilly and Company

Southern Research Institute

Ligand Pharmaceuticals, Inc.

La Jolla Institute for Allergy and Immunology

The Dupont Merck Pharmaceutical Company

Robert J Ardecky

Jiwen Zou

Ruth F Nutt

Anthony B Pinkerton

Joseph Edward Semple

William Charles Ripka

Terence Kevin Brunck

Matthew M Abelman

Yu Ge

John S Tyhonas

Susan Yoshiko Tamura

Dawn Alisa Brooks

Alan M Warshawsky

Christopher J Rito

Pierre-Yves Michellys

Marguerita S Lim-Wilby

Stephen H Carpenter

Santhi Reddy Ganji

Donald Paul Matthews

Samuel James Dominianni

Anthony John Shuker

Lynn Stacy Gossett

David A Hay

John J Duncia

Nicholas D P Cosford

Michael P Hedrick

Nunzio Bottini

Eduard A Sergienko

Stephanie M Stanford

Thomas D Y Chung

Marintha L Heil

David C Rowley

Marcos Gonzalez-Lopez

John Howard Hutchinson

Todd Kevin Jones

James R McCarthy

Lawrence G Hamann

Marcus F Boehm

Leonard Larry Winneroski, Jr

Ruth Richmond Wexler

Yanping Xu

James Russell Pruitt

David J Carini

Nathan Bryan Mantlo

Jung-Hui Sun

Alexander Glenn Godfrey

Pancras C Wong

Carlos Lamas-Peteira

Andrew T Chiu

Lourdes Prieto

Jyun-Hung Chen

Jose Alfredo Martin

Arthur D Patten

Carol L Ensinger

Sarah Beth Jones

Rafael Ferritto Crespo

Petrus B Timmermans

Anthony W Thompson

Christian A Hassig

Michael R Jackson

Isabel Rojo

Christopher M Mapes

Pierre Yves Michellys

Ian Pass

Leo Bleicher

Nick Cosford

Chahrzad Montrose-Rafezadeh

Anne-Reifel Miller

Maria Rosario Gonzales Garcia

Alicia Torrado

Maria Martin-Ortega Finger

Amy L Faulkner

Nicholas DP Cosford

Santhi R Ganji

Thomas Chung

Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

Herein are provided, inter, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof

Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A). 

Provided is a method for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus, as well as novel compounds that are useful in the method.

Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections

Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.

Inhibitors of glucocorticoid receptor translocation

Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.

Spirocyclic EBI2 modulators

Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.

EBI2 modulators

Provided is a process for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus. The process includes administering to the subject a therapeutically effective amount of at least one compound represented by the formula: (Formula (I)) 

The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.

Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof

Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, &#x2014;CH&#x2014; or &#x2014;CHCH&#x2014;; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to Rand W, Ris (CH)&#x2014;CH(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2550;C(OR)&#x2014;(CH)E, &#x2014;(CH)&#x2014;CH(Y)&#x2014;(CH)E or (CH)&#x2550;C(Y)&#x2014;(CH)E; wherein E is COOR, C&#x2013;Calkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C&#x2013;Calkyl, haloalkyl and aryl-C-4-alkyl; Ris H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, &#x2014;COR, &#x2014;COOR, &#x2014;CONRR, &#x2014;C(S)R, &#x2014;C(S)ORor C(S)NRR, Ris H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O&#x2014;, CH&#x2014;, &#x2014;CHCH&#x2014; or CH&#x2550;CH&#x2014; and is bonded to a carbon atom in Phenyl Ring A that is ortho to R. R&#x2013;Rare independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2 

Modulators of peroxisome proliferator activated receptors

Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof 

Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.

RXR modulators with improved pharmacologic profile

Growing community of inventors

Encinitas, CA, United States of America

Robert J Ardecky